Inhibitors of tumor necrosis factor for rheumatoid arthritis

Journal of Rheumatology

Volumn 26, Issue SUPPL. 57, 1999, Pages 7-15

  Moreland, Larry W ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Crohn's disease; Etanercept; Inflammation; Infliximab; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN FC FRAGMENT; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUKEMIA INHIBITORY FACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN DETECTION; APOPTOSIS; ARTHRALGIA; CONFERENCE PAPER; CYTOKINE RELEASE; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HLA SYSTEM; HORMONAL REGULATION; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEX RATIO;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; DRUG EVALUATION; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032945382     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Grossman JM, Brahn E. Rheumatoid arthritis: current clinical and research directions. J Womens Health 1997;6:627-38.
2. Körner H, Sedgwick JD. Tumour necrosis factor and lymphotoxin: molecular aspects and role in tissue-specific autoimmunity. Immunol Cell Biol 1996;74:465-72.
3. Moreland LW, Margolies G, Heck LW Jr, et al. Recombinant soluble TNF receptor (p80) fusion protein: toxicity and dose finding trial in refractory RA. J Rheumatol 1996:23:1849-55.
4. Moss ML, Jin SL, Becherer JD, et al. Structural features and biochemical properties of TNF-α converting enzyme. J Neuroimmunol 1997;72:127-9.
5. Merlos-Suárez A, Fernández-Larrea J, Reddy P, Baselga J, Arribas J. Pro-tumor necrosis factor-α processing activity is tightly controlled by a component that does not affect notch processing. J Biol Chem 1998:273:24955-62.
6. Paulus HE, Bulpitt KJ. Outcome measures. Rheum Dis Clin North Am 1995;21:605-18.
7. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
8. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
9. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-α. Arthritis Rheum 1993;36:1681-90.
10. Elliott MJ, Maini RN, Feldmann M, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor-α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
11. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumor necrosis factor-α (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
12. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antobody combined with low-dose weekly methotrexate in rheumatoid arthriris. Arthritis Rheum 1998;41:1552-63.
13. Segal R, Yaron M, Tartakovsky B. Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum 1990; 20:190-200.
14. Moreland LW, Baumgartner S, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
15. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial. Ann Intern Med 1999; (in press).
16. Coclet-Ninin J, Dayer JM, Burger D. Interferon-β not only inhibits interleukin-1β and tumor necrosis factor-α but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur Cytokine Netw 1997;8:345-9.
17. Cunnane G, Hummel KM, Muller-Ladner U, Gay RE, Gay S. Mechanism of joint destruction in rheumatoid arthritis. Arch Immunol Ther Exp (Warsz) 1998;46:1-7.
18. Koopman WJ, Moreland LW. Rheumatoid arthritis: anticytokine therapies on the horizon. Ann Intern Med 1998;128:231-3.
19. Evans CH, Ghivizzani SC, Robbins PD. Blocking cytokines with genes. J Leukoc Biol 1998;64:55-61.
20. Fisher CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996;334:1697-702.